Literature DB >> 3393785

Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes.

J Bisbe1, J M Gatell, J Puig, J Mallolas, J A Martinez, M T Jimenez de Anta, E Soriano.   

Abstract

One hundred thirty-three consecutive episodes of Pseudomonas aeruginosa bacteremia were prospectively followed in a university hospital over a 36-month period. The attack rate was 1.8 episodes per 1,000 discharges, and 85% of the episodes were hospital acquired. P. aeruginosa bacteremia represented 13.6% and 25.6% of the episodes of nosocomial bacteremia and gram-negative nosocomial bacteremia, respectively. The crude mortality rate was 50%. A stepwise logistic regression analysis defined four variables as independently influencing the outcome: development of septic shock (P = .00002), a granulocyte count less than 500/mm3 (P = .0008), inappropriate antibiotic therapy (P = .001), and the development of septic metastasis (P = .003). Among them, only the antibiotic treatment is easily amenable to medical intervention in order to improve the prognosis. Consequently, major efforts should focus on prevention and on the development of other therapeutic measures apart from antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393785     DOI: 10.1093/clinids/10.3.629

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  29 in total

1.  Rapid differentiation of fermentative from nonfermentative gram-negative bacilli in positive blood cultures by an impedance method.

Authors:  T C Chang; A H Huang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

2.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

3.  Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish hospital 1981-1990.

Authors:  F Vázquez; M C Mendoza; M H Villar; A Vindel; F J Méndez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

4.  Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.

Authors:  Sheryl Zelenitsky; Robert Ariano; Godfrey Harding; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 5.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Early and late onset bacteremia have different risk factors in trauma patients.

Authors:  M Antonelli; M L Moro; R R D'Errico; G Conti; M Bufi; A Gasparetto
Journal:  Intensive Care Med       Date:  1996-08       Impact factor: 17.440

7.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

8.  Nosocomial bacteremia in a medical-surgical intensive care unit: epidemiologic characteristics and factors influencing mortality in 111 episodes.

Authors:  J Rello; M Ricart; B Mirelis; E Quintana; M Gurgui; A Net; G Prats
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

9.  Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Authors:  Joshua T Thaden; Ashley E Keller; Norah J Shire; M Margarita Camara; Linda Otterson; Mike Huband; Caitlin M Guenther; Wei Zhao; Paul Warrener; C Kendall Stover; Vance G Fowler; Antonio DiGiandomenico
Journal:  J Infect Dis       Date:  2015-09-02       Impact factor: 5.226

Review 10.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.